Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease
Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease
The purpose of the study is to assess the safety and efficacy of hybrid revascularization in
 comparison with coronary artery bypass grafting among patients with multivessel coronary
 artery disease.
Inclusion Criteria:

 -  Age 18 or more

 -  Angiographically confirmed multivessel CAD with involved LAD and critical (>70%)lesion
 in at least one (apart LAD) major epicardial vessel amenable to both PCI and CABG

 -  Indication for revascularization based upon symptoms of angina and/or objective
 evidence of myocardial ischaemia

 -  Patient is willing to comply with all follow-up visits

 -  Patient signed an Informed Consent

 Exclusion Criteria:

 -  Severe congestive heart failure (class III or IV according to NYHA, or pulmonary
 edema, cardiogenic shock) at the time of enrollment

 -  Prior surgery with the opening of pericardium or pleura

 -  Prior stroke (within 6 months)or more than 6 months if there are substantial
 neurological defects

 -  Prior history of significant bleeding (within previous 6 months) that might be
 expected to occur during PCI/CABG related anticoagulation

 -  One or more chronic total occlusions in major coronary territories

 -  Left main stenosis (at least 50% diameter stenosis)

 -  Acute ST-elevation MI within 72 hours prior to enrollment requiring revascularization

 -  Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g.
 valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting)

 -  Contraindication to either CABG, MIDCAB or PCI/DES because of a coexisting clinical
 condition

 -  Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding
 diathesis.

 -  Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine

 -  Extra-cardiac illness that is expected to limit survival to less than 5 years e.g.
 oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or
 significant hepatic failure, severe renal disease

 -  Suspected pregnancy. A pregnancy test will be administered prerandomization to all
 women of child-bearing age

 -  Concurrent enrollment in another clinical trial

 -  Patient inaccessible for follow-up visits required by protocol